Dinutuximab (OP-08/Unituxin®)
Neuroblastoma
ApprovedCommercial
Key Facts
About Ohara Pharmaceutical
Japanese pharma company developing innovative and generic drugs for oncology, hepatology, and CNS disorders.
View full company profileTherapeutic Areas
Other Neuroblastoma Drugs
| Drug | Company | Phase |
|---|---|---|
| Neuroblastoma Risk Stratification | Quibim | Research |
| VNX-201 | Vironexis Biotherapeutics | Preclinical |
| GD2-GD3 Bispecific Vaccine | Y-mAbs Therapeutics | Early Clinical |
| DANYELZA® (naxitamab) | SERB Pharmaceuticals | Approved |
| GAIA-102 (fulamleucel) (iv + pretreatment) | GAIA BioMedicine | Early clinical trial |